Article Text

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
  1. Katja Hatz1,2,
  2. Frank Zimmermann3,
  3. Emmanouil Lazaridis4,
  4. Dimitrios Kardamakis5,
  5. Magdalena Guichard1,
  6. Cengiz Türksever1,
  7. Christian Pruente6,7,
  8. Ursula Margarethe Schmidt-Erfurth8,
  9. Bianca S Gerendas8
  1. 1 Vista Klinik, Binningen, Switzerland
  2. 2 University of Basel Faculty of Medicine, Basel, BS, Switzerland
  3. 3 Department of Radiation Oncology, University Hospital Basel, Basel, BS, Switzerland
  4. 4 EyeRAD Swiss Medical Center, Binningen, Switzerland
  5. 5 Department of Radiation Oncology, University of Patras Department of Medicine, Patras, Achaea, Greece
  6. 6 Department of Ophthalmology, University of Basel, Basel, BS, Switzerland
  7. 7 Institute of Molecular and Clinical Ophthalmology, Basel, Switzerland
  8. 8 Department of Ophthalmology and Optometry, Medical University of Vienna, Wien, Austria
  1. Correspondence to Dr Katja Hatz, Vista Klinik, Binningen, Binningen, Switzerland; katja.hatz{at}unibas.ch

Abstract

Background For treatment of neovascular age-related macular degeneration (nAMD), multiple intravitreal injections of drugs targeting vascular endothelial growth factors (VEGF) result in a high burden for patients and healthcare systems. Low-energy stereotactic radiotherapy (SRT) might reduce the anti-VEGF need. This study evaluated the long-term efficacy and safety of adjunct SRT to anti-VEGF injections in a treat-and-extend regimen in nAMD.

Methods 50 consecutive patients were followed 3 years after single-session SRT, a safety analysis including standardised study imaging, and a reading centre based image analysis was performed after 2 years.

Results After increase from baseline (4.24±0.66 weeks) to 12 months (7.52±3.05 weeks, p<0.001), mean recurrence-free anti-VEGF treatment interval remained stable at 24 (7.40±3.17, p=0.746) and 36 months (6.89±3.00, p=0.175). Mean visual acuity change was −5.8±15.9 and −11.0±20.1 letters at 24 and 36 months, respectively. 36% of eyes showed microvascular abnormalities (MVAs) on colour fundus photography and/or fluoresceine angiography most frequently located in parafoveal inferior and nasal regions.

Conclusion In real life, low-energy SRT was associated with a reduced anti-VEGF injection frequency through year 3. However, due to an observed visual acuity reduction and remarkable number of MVAs, a close follow-up of these patients is recommended. The real-life use, optimal treatment schedule and dose should be rediscussed critically.

  • retina
  • treatment other
  • macula

Data availability statement

Data are available on reasonable request. Patient data have been obtained in routine treatment and have been blinded. The patients have signed a general consent form.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available on reasonable request. Patient data have been obtained in routine treatment and have been blinded. The patients have signed a general consent form.

View Full Text

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Funding This study has been supported in part by Carl Zeiss Meditec AG Germany. The authors would like to thank the study coordinator Mrs Susanne Mueller and the chief photographer Mrs Christine Knodel for their support.

  • Disclaimer The industry contributor has had no role in the study and the manuscript.

  • Competing interests This study was supported in part by Carl-Zeiss Meditec AG, Germany (grant to KH, Vista Klinik). Carl-Zeiss Meditec AG, Germany, did not have any influence on the study protocol, study realisation, data analysis and interpretation.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Linked Articles

  • At a glance
    Frank Larkin